<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>After recent clinical trials, <z:chebi fb="0" ids="35664">statins</z:chebi> have gained increasing significance in secondary <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention </plain></SENT>
<SENT sid="1" pm="."><plain>From experimental studies, it is well established that <z:chebi fb="0" ids="35664">statins</z:chebi> have beneficial action when delivered prophylactically prior to a <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Conversely, much less is known about the effects of <z:chebi fb="0" ids="35664">statins</z:chebi> on injury development when delivered after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We here examined the effects of a post-ischemic delivery of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> (0.5, 5 or 20 mg/kg, administered i.p. immediately after reperfusion <z:hpo ids='HP_0003674'>onset</z:hpo>), a potent 3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitor, on brain injury and cell signaling after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, induced by 90 min of intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice </plain></SENT>
<SENT sid="4" pm="."><plain>In animals receiving <z:mpath ids='MPATH_458'>normal</z:mpath> saline, 0.5 or 5 mg/kg <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi>, middle cerebral <z:mp ids='MP_0006134'>artery occlusions</z:mp> resulted in reproducible brain <z:mpath ids='MPATH_124'>infarcts</z:mpath> at 24 h after reperfusion <z:hpo ids='HP_0003674'>onset</z:hpo>, which did not differ in size </plain></SENT>
<SENT sid="5" pm="."><plain>However, <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi>, administered at higher doses (20 mg/kg), reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume at 24 and 48 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (by 34+/-16% and 18+/-3%, respectively, P&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Western blots revealed that <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> decreased phosphorylated extracellular-regulated kinase-1/-2 and reduced activated caspase-3 levels in ischemic brain areas, while endothelial NO synthase expression, p38 and Jun kinase phosphorylation were not influenced by the 3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitor </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="38545">Rosuvastatin</z:chebi> also significantly diminished expression levels of inducible NO synthase in the ischemic brain </plain></SENT>
<SENT sid="8" pm="."><plain>Our results indicate that <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> may have utility not only as <z:hpo ids='HP_0001297'>stroke</z:hpo> prophylaxis but also as <z:hpo ids='HP_0011009'>acute</z:hpo> therapy inhibiting executive cell <z:hpo ids='HP_0011420'>death</z:hpo> pathways </plain></SENT>
</text></document>